Cited by 452BRCA gene mutations in cancerBreast Lesions and CarcinomasBreast Cancer Treatment Studies

The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

Verhoog, LC, Brekelmans, CTM, Seynaeve, C, van den Bosch, LMC, Dahmen, G, van Geel, AN, Tilanus-Linthorst, MMA, Bartels, CCM, Wagner, A, van den Ouweland, A, Devilee, P, Meijers-Heijboer, EJ, Klijn, JGM·1998·The Lancet

DOI 10.1016/s0140-6736(97)07065-7

Open this paper in CoChat — free account

Abstract

Background Hereditary breast cancer has been associated with mutations in the BRCA1 and BRCA2 genes and has a natural history different from sporadic breast cancer. We investigated disease-free and overall survival for patients with a proven BRCA1 alteration.Methods We estimated disease-free and overall survival for 49 Dutch patients from 19 consecutive families with a proven specific BRCA1 mutation and one family with strong evidence for linkage to the BRCA1 gene. We compared clinical outcome and data on tumour size, histology, axillary nodal status, contralateral breast cancer, and oestrogen-receptor and progesterone-receptor status with those of 196 patients with sporadic breast cancer, matched for age and year of diagnosis.Findings Disease-free survival for BRCA1 and sporadic patients at 5 years was 49% (95% CI 33-64) and 51% (43-59), respectively (p=0.98). Overall survival at 5 years was 63% (47-76) and 69% (62-76), respectively (p=0.88). Recurrence and death rates did not differ significantly between groups. Hazard ratios for recurrence and death among BRCA1 patients were 1.00 (0.65-1.55) and 1.04 (0.63-1.71) relative to sporadic patients (p=0.88), and these did not differ significantly after adjustment for prognostic factors. Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p<0.005) and development of contralateral breast cancer was four to five times as frequent as in the sporadic group (p<0.001).Interpretation We showed that disease-free and overall survival were similar for sporadic and hereditary breast cancer in the presence of different tumour characteristics, which has implications for screening prophylactic therapy, and different treatments of hereditary breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(97)07065-7

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
The statistical analysis of failure time data
Herson, J. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90009-x · Cited by 1,391
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Age as prognostic factor in premenopausal breast carcinoma
de la Rochefordière, A., Campana, F., Fenton, J., Vilcoq, J. R., Fourquet, A., Asselain, B. J. R., Scholl, S. M., Pouillart, P., Durand, J., & Magdelénat, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)92407-k · Cited by 481
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
Petrij-Bosch, A., Peelen, T., van Vliet, M., van Eijk, R., Olmer, R., Drüsedau, M., Hogervorst, F. B. L., Hageman, S., Arts, P. J. W., Ligtenberg, M. J. L., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-341 · Cited by 432
Self-citation
Tumour biological features of BRCA1-induced breast and ovarian cancer
Johannsson, O. T., Idvall, I., Anderson, C., Borg, Å., Barkardottir, R. B., Egilsson, V., & Olsson, H. L. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89007-7 · Cited by 344

Show all 31 references

Research works printed but not linked: 3

Lynch, 1993, Increased proliferation in hereditary breast cancer, Proc ASCO, 12, 82
Lynch, 1994, Distinctive clinicopathological features of BRCA1 linked hereditary breast cancer, Proc ASCO, 13, 56
Solin, 1996, Breast cancer in young women: the University of Pennsylvania experience—breast cancer: advances in biology and therapeutics, John Libbey Eurotext, 351

Sorted by citations

Items 201–300 of 450

Reading between the lines: Direct-to-consumer advertising of genetic testing in the USA
Hull, S. C., & Prasad, K. (2001) · Reproductive Health Matters · doi:10.1016/s0968-8080(01)90089-8 · Cited by 31
Risk factors for breast cancer
Falkenberry, S. S., & Legare, R. D. (2002) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(03)00059-7 · Cited by 31
Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis
Liu, M., Xie, F., Liu, M., Zhang, Y., & Wang, S. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06104-y · Cited by 29
Molecular genetics analysis of hereditary breast and ovarian cancer patients in India
Soumittra, N., Meenakumari, B., Parija, T., Veluswami, S., Nancy, N. K., Swaminathan, R., Rajalekshmy, K. R., Majhi, U., & Rajkumar, T. (2009) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-7-13 · Cited by 28
BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer
Sabatier, R., Adélaı̈de, J., Finetti, P., Ferrari, A., Huiart, L., Sobol, H., Chaffanet, M., Birnbaum, D., & Bertucci, F. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20822 · Cited by 28
Family history of breast cancer in relation to tumor characteristics and mortality in a population--based study of young women with invasive breast cancer
Malone, K., Daling, J., Doody, D., O'Brien, C. A., Resler, A. J., Ostrander, E., & Porter, P. (2011) · Cancer Epidemiology, Biomarkers and Prevention · doi:10.1158/1055-9965.epi-11-0781 · Cited by 35
Prevalence of BRCA1 and BRCA2 mutations in women with carcinoma in situ of the breast referred for genetic testing
Hall, M., Reid, J., & Wenstrup, R. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0218 · Cited by 30
Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1
Judkins, T., Hendrickson, B. C., Deffenbaugh, A. M., & Scholl, T. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.07.024 · Cited by 28
Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Ansquer, Y., Mandelbrot, L., Lehy, T., Salomon, L., Dhainaut, C., Madélénat, P., Feldmann, G., & Walker, F. (2005) · PubMed · Cited by 28
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women
Querzoli, P., Albonico, G., di Iasio, M. G., Ferretti, S., Rinaldi, R., Cariello, A., Pedriali, M., Matteuzzi, M., Maestri, I., & Nenci, I. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010643515095 · Cited by 28
Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain)
de Sabando, A. R., Lafuente, E. U., García-Amigot, F., Sánchez, A. A., Garofalo, L. M., Moreno, S., Ardanáz, E., & Ramos‐Arroyo, M. A. (2019) · BMC Cancer · doi:10.1186/s12885-019-6277-x · Cited by 27
New approaches to surgery for breast cancer.
Singletary, S. E. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080265 · Cited by 27
Management of Hereditary Breast Cancer
Eccles, D., Simmonds, P., Goddards, J., Coultas, M., Lalloo, F. I., Evans, D. G., & Haites, N. E. (1999) · Disease Markers · doi:10.1155/1999/809015 · Cited by 26
Low frequency of lymph-node metastasis in BRCA1-associated breast cancer
Eisinger, F., Noguès, C., Birnbaum, D., Jacquemier, J. D., & Sobol, H. (1998) · The Lancet · doi:10.1016/s0140-6736(05)77689-3 · Cited by 26
Gene-Expression Profiles in Hereditary Breast Cancer
(2001) · New England Journal of Medicine · doi:10.1056/nejm200108233450822 · Cited by 28
Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients
Kim, E., Park, S. Y., & Kim, S. (2020) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2020.04.07 · Cited by 25
Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist’s point of view
Vallard, A., Magné, N., Guy, J., Espenel, S., Rancoule, C., diao, P., Deutsch, É., Rivera, S., & Chargari, C. (2019) · British Journal of Radiology · doi:10.1259/bjr.20170657 · Cited by 25
Survival analysis in familial ovarian cancer, a case control study.
Zweemer, R., Verheijen, R., Coebergh, J., Jacobs, I., van Diest, P. V., Gille, J., Skates, S., Menko, F. H., ten Kate, L. T., & Kenemans, P. (2001) · European Journal of Obstetrics, Gynecology, and Reproductive Biology · doi:10.1016/s0301-2115(01)00318-9 · Cited by 22
Androgen Pathway Dysregulation in BRCA1-Mutated Breast Tumors
Berns, E. M. J. J., Dirkzwager-Kiel, M. M., Kuenen‐Boumeester, V., Timmermans, M. A. M., Verhoog, L. C., van den Ouweland, A. M. W., Meijers-Heijboer, H. E. J., Klijn, J. G. M., & van der Kwast, T. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023347409599 · Cited by 25
Self-citation
Conservative management of breast cancer in BRCA1/2 mutation carriers.
Alpert, T. E., & Haffty, B. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.008 · Cited by 26
Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients
Park, S., Noh, S. J., Kim, K. M., Bae, J. S., Kwon, K. S., Jung, S. H., Kim, J. R., Lee, H., Chung, M. J., Moon, W. S., et al. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.04.004 · Cited by 24
Endocrinology of the Wild and Mutant Brca1 Gene and Types of Hormonal Carcinogenesis
Berstein, L. M. (2008) · Future Oncology · doi:10.2217/14796694.4.1.23 · Cited by 23
Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients
de Bock, G. H., Tollenaar, R. A. �. �., Papelard, H., Cornelisse, C. J., Devilee, P., & van de Vijver, M. J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2103 · Cited by 23
Self-citation
Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation
Hanus, M. C., Zagars, G. K., & Pollack, A. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00408-8 · Cited by 23
Hereditary Susceptibility to Breast Cancer: Significance of Age of Onset in Family History and Contribution of BRCA1 and BRCA2
Frank, T. S., Deffenbaugh, A. M., Hulick, M., & Gumpper, K. (2002) · Disease Markers · doi:10.1155/1999/291023 · Cited by 11
Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama.
Marchetti, P., Rocco, C. D., Ricevuto, E., Bisegna, R., Cianci, G., Calista, F., Sidoni, T., Porzio, G., & Ficorella, C. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh654 · Cited by 22
Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
Vogel, V. G. (2001) · PubMed · Cited by 23
BREAST CANCER GENETICS: Implications for Clinical Practice
Olopade, O., & Fackenthal, J. (2000) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70304-x · Cited by 22
Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
Evans, D. G., & Howell, A. (2003) · Breast Cancer Research · doi:10.1186/bcr748 · Cited by 23
Re: Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations
Brown, D. L., Cole, B. F., & Arrick, B. A. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.90a · Cited by 23
Implementation of Genetics to Personalize Medicine
Chung, W. K. (2007) · Gender Medicine · doi:10.1016/s1550-8579(07)80044-1 · Cited by 23
Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics
Eccles, D. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh917 · Cited by 22
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients
Su, L., Xu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2020) · International Journal of Cancer · doi:10.1002/ijc.32918 · Cited by 22
The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer
Chen, L., Fu, F., Huang, M., Lv, J., Zhang, W., & Wang, C. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05573-x · Cited by 21
Primary Acinic Cell Carcinoma of the Breast: A Clinicopathological and Immunohistochemical Study
Shingū, K., Ito, T., Kaneko, G., & Itoh, N. (2013) · Case Reports in Oncological Medicine · doi:10.1155/2013/372947 · Cited by 21
Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population
Wong, E. S. Y., Shekar, S., Chan, C. H. T., Hong, L. Z., Poon, S.-Y., Silla, T., Lin, C. B., Kumar, V., Dávila, S., Voorhoeve, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134408 · Cited by 21
BRCA1/2 in High-Risk African American Women with Breast Cancer: Providing Genetic Testing through Various Recruitment Strategies
Pal, T., Vadaparampil, S. T., Betts, J., Miree, C. A., Li, S., & Narod, S. A. (2008) · Genetic Testing · doi:10.1089/gte.2007.0108 · Cited by 20
Genetic testing for breast and ovarian cancer susceptibility: a family experience.
Riper, M. V., & Mckinnon, W. (2004) · Journal of midwifery & women's health · doi:10.1016/j.jmwh.2004.01.021 · Cited by 22
Rates of BRCA1/2 mutation testing among young survivors of breast cancer
Kehl, K., Shen, C., Litton, J., Arun, B., & Giordano, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3658-y · Cited by 24
Management of familial breast cancer risk
Goodwin, P. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006470206271 · Cited by 25
Are Medullary Breast Cancers an Indication for BRCA1 Mutation Screening? A Mutation Analysis of 42 Cases of Medullary Breast Cancer
Iau, P., Marafie, M., Ali, A., Sng, J., Macmillan, R., Pinder, S., Denley, H., Ellis, I., Wenzyck, P., Scott, N., et al. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000021049.61839.e5 · Cited by 17
Hormonal interventions to prevent hormonal cancers: breast and prostate cancers
Dunn, B., & Ford, L. (2007) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e328011ed2d · Cited by 20
Pathological characteristics of BRCA-associated breast cancers in Hispanics
Lagos, V. I., Press, M. F., Ricker, C. N., Dubeau, L., Mai, P. L., & Weitzel, J. N. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1570-7 · Cited by 18
Prophylactic Mastectomy
Zakaria, S., & Degnim, A. C. (2007) · Surgical Clinics of North America · doi:10.1016/j.suc.2007.01.009 · Cited by 18
Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas
Mylona, E. E., Melissaris, S., Nomikos, A., Theohari, I., Giannopoulou, I., Tzelepis, K., & Nakopoulou, L. (2014) · Pathology - Research and Practice · doi:10.1016/j.prp.2014.05.009 · Cited by 17
BRCA1 and BRCA2: a small part of the puzzle.
Burke, W., Press, N., & Pinsky, L. E. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.904 · Cited by 18
Fine tuning chemotherapy to match BRCA1 status
Price, M. L., & Monteiro, Á. N. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.015 · Cited by 17
Pineal Parenchymal Tumours: I
Jackson, A., & Plowman, P. N. (2004) · Clinical Oncology · doi:10.1016/j.clon.2003.11.016 · Cited by 16
Hereditary risk of women's cancers.
Frank, T. S., & Critchfield, G. (2002) · Best Practice & Research: Clinical Obstetrics & Gynaecology · doi:10.1053/beog.2002.0313 · Cited by 16
Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas.
Pierce, L. (2002) · Seminars in Radiation Oncology · doi:10.1053/srao.2002.35254 · Cited by 17
Mathematical models of the steps involved in the systemic delivery of a chemotherapeutic to a solid tumor: From circulation to survival
Ulmschneider, M. B., & Searson, P. C. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.026 · Cited by 17
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer
Lakhani, S. R. (2001) · Molecular Pathology · doi:10.1136/mp.54.5.281 · Cited by 16
Survival of patients with breast cancer and BRCA1 mutations
Foulkes, W. D., Wong, N., Rozen, F., Brunet, J., & Narod, S. A. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79091-7 · Cited by 16
If you care about women's health, perhaps you should care about the risks of direct marketing of tamoxifen to consumers.
Press, N. A., & Burke, W. (2000) · PubMed · Cited by 15
Mastectomy for risk reduction or symmetry in women without high risk gene mutation: A review
Kenny, R., Reed, M., & Subramanian, A. (2017) · International Journal of Surgery · doi:10.1016/j.ijsu.2017.12.022 · Cited by 13
Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis
Tinterri, C., Grimaldi, S. D. M., Sagona, A., Barbieri, E., Darwish, S. S., Bottini, A., Canavese, G., & Gentile, D. (2023) · Cancers · doi:10.3390/cancers15164177 · Cited by 15
Current status of prophylactic mastectomy.
Ghosh, K., & Hartmann, L. C. (2002) · PubMed · Cited by 15
Outcomes and risk of subsequent breast events in breast‐conserving surgery patients with BRCA1 and BRCA2 mutation
Ye, F., Huang, L., Lang, G., Hu, X., Di, G., Shao, Z., & Cao, A. (2020) · Cancer Medicine · doi:10.1002/cam4.2836 · Cited by 15
Knowledge about breast cancer risk factors and hereditary breast cancer among early-onset breast cancer survivors
Miesfeldt, S., Cohn, W. F., Ropka, M. E., & Jones, S. (2001) · Familial Cancer · doi:10.1023/a:1021189128084 · Cited by 15
Treatment of Hereditary Breast Cancer
Robson, M. E. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.07.011 · Cited by 15
Accumulation of aberrant Y chromosomes in ?-ray-induced thymic lymphomas lacking p53
Chou, D., Matsuki, J., Saitou, Y., Kosugi, S., Shinbo, T., Gejyo, F., Niwa, O., & Kominami, R. (1999) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199911)26:3 · Cited by 1
The Contribution of Inherited Factors to the Clinicopathological Features and Behavior of Breast Cancer
Foulkes, W. D., Rosenblatt, J. M., & Chappuis, P. O. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1014791115760 · Cited by 15
Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2.
Coleman, C. (1999) · Acta oncologica · doi:10.1080/028418699432770 · Cited by 13
Response to Ovarian Stimulation for Urgent Fertility Preservation before Gonadotoxic Treatment in BRCA-Pathogenic-Variant-Positive Breast Cancer Patients
Moujahed, L. E., Philis, R., Grynberg, M., Laot, L., Mur, P., Amsellem, N., Mayeur, A., Benoit, A., Rakrouki, S., Sifer, C., et al. (2023) · Cancers · doi:10.3390/cancers15030895 · Cited by 14
Pathologic Features and Immunophenotype of Estrogen Receptor–positive Breast Cancers in BRCA1 Mutation Carriers
Kaplan, J. S., Schnitt, S. J., Collins, L. C., Wang, Y., Garber, J. E., Montgomery, K. D., West, R. B., Krag, K. J., Fetten, K., Lincoln, A., et al. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31825789ed · Cited by 14
When is contralateral mastectomy warranted in unilateral breast cancer?
Barry, M., & Sacchini, V. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.100 · Cited by 14
Genetic Testing for Hereditary Breast Cancer: The Decision to Decline
White, V., Walsh, K. K., Foss, K., Amacker-North, L., Lenarcic, S., McNeely, L., & White, R. L. (2018) · The American Surgeon · doi:10.1177/000313481808400139 · Cited by 14
Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report
Dudaladava, V., Jarząb, M., Stobiecka, E., Chmielik, E., Simek, K., Huzarski, T., Lubiński, J., Pamuła‐Piłat, J., Pękala, W., Grzybowska, E. A., et al. (2006) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-4-1-28 · Cited by 14
Identifying and managing hereditary risk of breast and ovarian cancer.
Frank, T. S., & Critchfield, G. (2001) · Clinics of Perinatology · doi:10.1016/s0095-5108(05)70091-9 · Cited by 16
Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option?
Haffty, B. G., & Lannin, D. R. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.032 · Cited by 14
Host susceptibility to cancer progression.
Narod, S. (1998) · American Journal of Human Genetics · doi:10.1086/301939 · Cited by 16
A 40-Year-Old Woman With a Strong Family History of Breast Cancer
Garber, J. E. (1999) · JAMA · doi:10.1001/jama.282.20.1953 · Cited by 14
Modified Radical Mastectomy and Simple Mastectomy
Bland, K. I., Chang, H. R., & Copeland, E. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00031-3 · Cited by 13
Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer
Lan, Y., Zhao, E., Luo, S., Xiao, Y., Li, X., & Cheng, S. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05153-8 · Cited by 13
The pathology of familial breast cancer: Clinical and geneticcounselling implications of breast cancer pathology
Lalloo, F. I., & Evans, D. G. (1999) · Breast Cancer Research · doi:10.1186/bcr13 · Cited by 13
A hypothesis about tumour development and the clinical features of hereditary breast cancers
Olsson, H. L. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00228-3 · Cited by 13
Considerations arising from requests from patients for a bilateral mastectomy who are eligible for breast-conserving surgery: Factors weighing for and against performing the operation
Fancellu, A. (2016) · Oncology Letters · doi:10.3892/ol.2016.4641 · Cited by 12
Breast Cancer Screening, Outside the Population-Screening Program, of Women from Breast Cancer Families without Proven BRCA1/BRCA2 Mutations: a Simulation Study
Jacobi, C. E., Nagelkerke, N. J. D., van Houwelingen, H. C., & de Bock, G. H. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0223 · Cited by 12
Hereditary Breast and Ovarian Cancer: What the Primary Care Physician Should Know
Khoury-Collado, F., & Bombard, A. (2004) · Obstetrical and Gynecological Survey · doi:10.1097/00006254-200407000-00023 · Cited by 16
Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist.
Frank, T. S. (1998) · The Oncologist · doi:10.1634/theoncologist.3-6-403 · Cited by 12
Concordance of Hormone Receptor Status and BRCA1/2 Mutation Among Women With Synchronous Bilateral Breast Cancer
Huang, L., Liu, Q., Lang, G., Cao, A., & Shao, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00027 · Cited by 11
Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration
Yoshimura, A., Yokoyama, S., Iwata, H., Takaiso, N., Nomizu, T., Arai, M., & Nakamura, S. (2020) · Journal of Human Genetics · doi:10.1038/s10038-020-00850-5 · Cited by 11
Breast MRI as a Screening Tool: The Appropriate Role
Le‐Petross, H. T. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.0042 · Cited by 11
An audit of screening for familial breast cancer before 50 years in the South Thames Region – have we got it right?
Murday, V. A., Pears, R., Ball, J., Eeles, R. A., & Hodgson, S. V. (2004) · Familial Cancer · doi:10.1023/b:fame.0000026818.34049.84 · Cited by 11
Amplification ofTOP2AandHER-2genes in breast cancers occurring in patients harbouringBRCA1germline mutations
Hagen, A. I., Bofin, A. M., Ytterhus, B., Mæhle, L., Kjellevold, K. H., Myhre, H. O., Møller, P., & Lønning, P. E. (2007) · Acta Oncologica · doi:10.1080/02841860600949552 · Cited by 11
Laboratory Determination of Hereditary Susceptibility to Breast and Ovarian Cancer
Frank, T. S. (1999) · Archives of Pathology & Laboratory Medicine · doi:10.5858/1999-123-1023-ldohst · Cited by 11
Prognostic and Predictive Factors in Breast Cancer
Klijn, J. G. M., Berns, E. M. J. J., & Foekens, J. A. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-699-7_14 · Cited by 11
Self-citation
The Impact of Molecular Diagnostic Tests on Patient Outcomes
Ross, J. S. (1999) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30092-1 · Cited by 11
PREDICTIVE GENETIC TESTING FOR BREAST AND PROSTATE CANCER
Noorani, H. Z. (1999) · DigitalGeorgetown (Georgetown University Library) · Cited by 11
The Key and the Lamppost
Hellmän, S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3007 · Cited by 11
Letter to the Editor
Benson, J. R., & Osborne, M. P. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006217007055 · Cited by 11
Surgical Management of Hereditary Breast Cancer
Berger, E. R., & Golshan, M. A. (2021) · Genes · doi:10.3390/genes12091371 · Cited by 13
Hereditary breast cancer syndromes and clinical implications
Majdak-Paredes, E. J., & Fatah, F. (2008) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2008.07.012 · Cited by 11
Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate‐risk and low‐risk individuals – correlation with clinicopathological data
Kataki, A., Gomatos, I., Pararas, N. B., Armakolas, A., Panoussopoulos, D. G., Καραντζίκος, Γ.-Α., Voros, D. C., Zografos, G., Markopoulos, C. J., Leandros, E., et al. (2005) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00400.x · Cited by 10
GENETIC TESTING FOR BREAST CANCER PREDISPOSITION
Gauthier‐Villars, M., Gad, S., Caux‐Moncoutier, V., Pagès-Berhouet, S., Blandy, C., & Stoppa‐Lyonnet, D. (1999) · Surgical Clinics of North America · doi:10.1016/s0039-6109(05)70067-0 · Cited by 10
Molecular genetics and the assessment of human cancers
Caldas, C., & Pharoah, P. (1999) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399499000526 · Cited by 9
Evaluation of alternative methods of cervical cancer screening for resource-poor settings
Denny, L., Kuhn, L., Pollack, A. E., Wainwright, H., & Wright, T. C. (2000) · Cancer · doi:10.1002/1097-0142(20000815)89:4 · Cited by 250
Prophylactic and Therapeutic Breast Conservation inBRCA1/2Mutation Carriers
Croshaw, R. L., Marshall, M. L., Williams, T. L., Erb, K. M., & Julian, T. B. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/481563 · Cited by 9
The immune regulation and therapeutic potential of the SMAD gene family in breast cancer
Chen, Z., Wang, Y., Lu, X., Chen, H., Kong, Y., Rong, L., & Wang, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-57189-6 · Cited by 9
Dissimilarity between sporadic, non-BRCA1/2 families and hereditary breast cancer, linked to BRCA genes, in the Tunisian population
Riahi, A., el Gourabi, M., & Chaabouni-Bouhamed, H. (2015) · Breast Cancer · doi:10.1007/s12282-015-0648-1 · Cited by 9

Authors: Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., Devilee, P., Meijers-Heijboer, E., & Klijn, J.
Affiliations: Academisch Ziekenhuis Rotterdam (NL)
Erasmus University Rotterdam (NL)
Leiden University (NL)
Corresponding author: Klijn, JGM
ORCID: Wagner, A
Devilee, P
Venue: The Lancet
Publisher: Elsevier BV
Published: 1998-01
Volume: 351
Issue: 9099
Pages: 316-321
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(97)07065-7
OpenAlex: W2137086763
Cited by: 452
References: 31
Citations by year: 2026: 3 · 2025: 8 · 2024: 3 · 2023: 7 · 2022: 1 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 13 · 2014: 10 · 2013: 7 · 2012: 5
FWCI: 28.46
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Funders: KWF Kankerbestrijding
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: hereditary breast cancer, BRCA1 mutation, sporadic breast cancer, disease-free survival, overall survival, contralateral breast cancer, estrogen receptor status, tumor characteristics, tumor recurrence, breast cancer screening
MeSH terms: Adult, Aged, Breast Neoplasms, Female, Humans, Middle Aged, Prognosis, Risk, Odds Ratio, Survival Analysis, Germ-Line Mutation, Disease-Free Survival, Genes, BRCA1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks